fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA Advisory Committee recommends belantamab mafodotin to treat relapsed or refractory multiple myeloma.- GSK

Written by | 17 Jul 2020

GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.

PT 20 iron-based phosphate binder study is published in Nephrology Dialysis Transplantation.-Shield Therapeutics

Written by | 17 Jul 2020

Shield Therapeutics plc a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication in Nephrology… read more.

FDA Advisory Committee recommends belantamab mafodotin to treat relapsed or refractory multiple myeloma.- GSK

Written by | 17 Jul 2020

GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.

The New England Journal of Medicine publishes positive phase IIb trial of topical roflumilast cream for chronic plaque psoriasis.- Arcutis Biotherapeutics.

Written by | 17 Jul 2020

Arcutis Biotherapeutics, Inc. ,announced that The New England Journal of Medicine has published positive results from a Phase IIb trial of its investigational drug topical roflumilast cream for… read more.

BAY 1021189 filed with FDA for heart failure.- Merck Inc

Written by | 17 Jul 2020

Merck Inc., announced that the FDA has accepted for priority review the New Drug Application (NDA) for BAY 1021189 (vericiguat), an orally administered soluble guanylate cyclase (sGC) stimulator,… read more.

FDA Advisory Committee recommends belantamab mafodotin to treat relapsed or refractory multiple myeloma.- GSK

Written by | 17 Jul 2020

GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.

Publication in The New England Journal of Medicine of interim results from phase 1 study of the mRNA vaccine against COVID-19 (mRNA-1273).- Moderna Inc.

Written by | 16 Jul 2020

Moderna, Inc. announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of… read more.

Initiation of an investigator-sponsored trial by Imperial College London to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia. Rigel Pharma

Written by | 16 Jul 2020

Rigel Pharmaceuticals, Inc. announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase… read more.

Brilinta significantly reduced the rate of the composite of stroke and death in patients who had an acute ischaemic stroke or TIA in the phase III THALES trial.- AstraZeneca

Written by | 16 Jul 2020

Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate… read more.

Advisory Committee Meeting recommends terlipressin to treat adults with hepatorenal syndrome type 1.- Mallinckrodt

Written by | 16 Jul 2020

Mallinckrodt Plc announced that the Cardiovascular And Renal Drugs Advisory Committee of the U.S. FDA voted to recommend approval for its investigational agent terlipressin to treat adults with… read more.

Eiasi initiates a new Phase III clinical study (AHEAD 3-45) of BAN 2401 for individuals with preclinical Alzheimer’s disease.

Written by | 14 Jul 2020

The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study (AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.

Eiasi initiates a new Phase III clinical study ?AHEAD 3-45) of BAN 2401 for individuals with preclinical Alzheimer’s disease.

Written by | 14 Jul 2020

The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study ?AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.